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ABSTRACT 
Objective: The objective of this research was to develop a novel liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the 
determination of irbesartan in human plasma. 
Methods: An analytical method based on liquid chromatography/tandem mass spectrometry (LC-MS/MS) has been developed and validated for the 
quantitative determination of irbesartan in human plasma. The method utilizes irbesartan d4 as internal standard (IS). After solid phase extraction 
(SPE), analyte and the IS were chromato graphed on a C18
Results: Precision and accuracy of the method was determined using five analytical batches in the concentration range of 50.0–9982 ng/ml. All the 
validation experiments were carried out as per the US FDA guidelines and results met the acceptance criteria.  
 columns using a isocratic mobile phase composed of methanol–0.2% formic acid (85:15, 
v/v) pumped at a flow rate of 0.70 mL/min.  
Conclusion: The proposed LC–MS/MS assay method is simple, rapid and enough sensitive for the determination of irbesartan in human plasma. A 
chromatographic run time set at 2.0 min, thus can analyze more than 300 samples in a day. Also, the proposed method was found to be applicable to 
clinical studies.  
Keywords: Irbesartan, Solid–phase extraction (SPE), LC-MS/MS, Method validation, Pharmacokinetics. 
 
INTRODUCTION 
Angiotensin II is the primary vasoactive hormone in the renin-
angiotensin system. Its effects include vasoconstriction and the 
stimulation of aldosterone secretion by the adrenal cortex. 
Irbesartan antagonizes angiotensin II by blocking AT1 receptors. 
The drug used mainly for the treatment of hypertension. Irbesartan 
is an orally active agent, with bioavailability of 60-80%. Following 
oral administration, peak plasma concentrations are attained at 1.5-
2 hours after dosing. The drug has the terminal elimination half-life 
of 11-15 hours [1, 2]. 
Literatures survey reveals, many analytical method based on liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) [3-7], 
ultra-performance liquid chromatography-tandem mass 
spectrometry method (UPLC-MS/MS) [8, 9] and mass spectrometry 
with time-of-flight detection (MALDI-TOF MS) [10, 11] have been 
reported for the determination of irbesartan in a variety of biological 
samples. MALDI-TOF MS is a high throughput technique widely used 
in high molecular weight compound (such as proteins or polymers) 
analysis, but rarely used in low molecular weight compound 
analysis. Similarly, UPLC-MS/MS is an ultra-fast techniques 
possesses advantage of high sensitivity and high sample throughput 
over conventional LC-MS systems [12, 13]. Of all the methods 
reported above, only LC-MS/MS are comparable with the present 
work. Tutunji et al., 2010 [3] reported a method for the 
simultaneous determination of irbesartan and hydrochlorothiazide 
in 250 µl of human plasma. Similarly, Prasad et al., 2009 [4] 
published a method for the simultaneous determination of 
irbesartan and losartan in rat plasma. Both the methods employs 
protein precipitation (PP) technique for sample preparation with 
the chromatographic run time of>4 min, which may not be suitable 
for routine drug analysis. PP is most likely to cause ion suppression 
and not efficient to remove the endogenous compounds such as 
lipids, phospholipids and fatty acids completely. Another method 
reported by Ganesan et al., 2010 [5] for the determination of 
irbesartan in 100 µl of human plasma, this method employs liquid–
liquid (L–L) extract, evaporation, drying and reconstitution for 
sample preparation. Ferreirós et al., 2007 [6] reported a LC-MS/MS 
method for the quantitation of angiotensin II receptor antagonists 
(ARA-II) in human plasma. This method is not specific for the 
irbesartan and it may create conflicts in the final results due to 
improper characterization of selectivity. A promising method was 
reported by Tiwari et al., 2013 [7] for the determination in 
irbesartan in human and dog plasma samples with the linearity 
range of 12.1 to 6018.7 ng/ml using candesartan as internal 
standard. However, this method is also having the limitation in 
chromatographic run time>3 min, which may not be suitable for the 
high through put bio analysis of irbesartan. The analytical method 
should gratify the scientists in terms of simplicity, sensitivity, 
runtime, sample volume, time consumption and efficient extraction 
procedure. 
The present paper describes a simple, selective and sensitive liquid 
chromatography–electro spray ionization tandem mass 
spectrometry (LC–MS/MS) assay method for the determination of 
irbesartan in human plasma using irbesartan d4, as an internal 
standard (IS). Use of isotope labeled compounds as internal 
standards minimizes matrix effect related problems and variability 
in recovery between analyte and the IS. This method requires only 
50 µl human plasma for solid–phase extraction (SPE) technique 
without drying, evaporation and reconstitution steps, and minimum 
usage of organic solvents and demonstrates excellent performance 
in terms of ruggedness with a sample cut off time 2.0 min. 
MATERIALS AND METHODS  
Standards and chemicals 
The reference sample of irbesartan (99.44%) was obtained from 
Hetero Drugs Limited (Hyderabad, India), while irbesartan d4 
(97.90%) was from Clearsynth Ltd., (Mumbai, India). Their 
structures are presented in fig. 1. Water used for the LC–MS/MS 
analysis was prepared by using Milli Q water purification system 
procured from Millipore (Bangalore, India). HPLC grade methanol 
was purchased from J. T. Baker (Phillipsburg, USA). Analytical grade 
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formic acid and ammonium acetate was purchased from Merck Ltd 
(Mumbai, India). The control K2
 
 human plasma sample was 




Irbesartan d4 (IS) 
Fig. 1: Chemical structures of irbesartan and irbesartan d4 (IS) 
 
LC–MS/MS instrument and conditions 
An HPLC system (Shimadzu, Kyoto, Japan) equipped with a Hypurity 
Advance (50 mm × 4.6 mm, 5 µm) (Make: Thermo scientific), a 
binary LC–20AD prominence pump, an auto sampler (SIL–HTc) and 
a solvent degasser (DGU–20A3) was used for the study. An aliquot of 
15 µl of the processed sample was injected in to the liquid 
chromatographic system. An isocratic mobile phase composed of a 
mixture of 0.2% formic acid and methanol (15:85, v/v) was used to 
separate the analyte from the endogenous components and pumped 
at a flow rate of 0.70 mL/min (with splitter) into the electro spray 
ionization chamber of the mass spectrometer. Quantification was 
achieved with MS–MS detection in positive ion mode for the analyte 
and the IS using an AB Sciex API–3000 mass spectrometer (Foster 
City, CA, USA) equipped with a Turboion spray ™ interface at 500 °C. 
The ion spray voltage was set at 5000 V.  
The source parameters viz. the nebulizer gas (GS1), curtain gas and 
collision gas were set at 5, 15, and 7 psi, respectively. The compound 
parameters viz. the declustering potential (DP), collision energy 
(CE), entrance potential (EP) and collision cell exit potential (CXP) 
were 22, 35, 10, 12 V for irbesartan and for the IS. Detection of the 
ions was carried out in the multiple–reaction monitoring mode 
(MRM), by monitoring the transition pairs of m/z 429.5 precursor 
ion to the m/z 207.0 for irbesartan and m/z 433.5 precursor ion to 
the m/z 211.0 production for the IS. Quadrupoles (Q1 and Q3) were 
set on unit resolution. Dwell time was set at 200 ms. The analysis 
data obtained were processed by Analyst software™ (version 1.4.2).  
Preparation of calibration curve standards and quality control 
samples in human plasma 
Two standard stock solutions of irbesartan were prepared 
separately in HPLC grade methanol (1 mg/ml) for the preparation of 
calibration curve standards and quality control samples, 
respectively. Further dilutions of analyte were prepared in a mixture 
of methanol and water (50:50, v/v; diluent). A 1 mg/ml of irbesartan 
d4 stock solution was prepared by dissolving the compound in HPLC 
grade methanol. The working concentration of irbesartan d4 (25.0 
ng/ml) was prepared from the above stock solution using the 
diluent. 
Calibration samples were prepared by spiking 950 µl of control K2
Sample processing procedure 
 
EDTA human plasma with the 50 µl working standard solution of the 
analyte as a bulk, to obtain riluzole concentration levels of 50.0, 100, 
200, 500, 1000, 2000, 4001, 5989, 7986 and 9982 ng/ml as a single 
batch at each concentration. Similarly, quality control (QC) samples 
were also prepared as a bulk based on an independent weighing of 
standard drug, at concentrations of 50.3 (lower limit of quantitation 
quality control, LLOQ QC), 144 (low quality control, LQC), 1105 
(medium quality control, MQC1), 5022 (MQC2) and 8968 ng/ml 
(high quality control, HQC) as a single batch at each concentration. 
A 50 µl aliquot of human plasma sample was mixed with 10 μL of the 
internal standard working solution (25.0 ng/ml of irbesartan d4). To 
this, 100 μL of 2% formic acid was added. The extraction cartridges 
(Strata-X, 33 µm polymeric sorbent) were conditioned with 1.0 mL 
of methanol followed by 1.0 mL of water and 1.0 mL of 2% formic 
acid solution. Then, the entire sample mixture was loaded on to a 
cartridge and elute with a gentle stream of nitrogen. The extraction 
cartridge was washed with 1.0 mL of 100 mM ammonium acetate 
followed by 1.0 mL of water. Analyte and the IS were eluted with 
0.50 mL of mobile phase. Aliquot of 15 μL of the extract was injected 
into the LC-MS/MS system. 
Method validation parameters 
A complete and through, method validation was carried out as per recent 
US FDA guidelines [14]. The parameters determined were carryover test, 
matrix effect, selectivity, sensitivity, linearity, precision and accuracy, 
dilution integrity, recovery, and various stabilities. 
Pharmacokinetic study protocol design  
The proposed method was successfully applied to a pharmacokinetic 
study in South Indian male subjects (n = 7). The subjects with body 
body–mass index (BMI) of ≥18.5 kg/m2 and ≤24.9 kg/m2
RESULTS AND DISCUSSION 
, with body 
weight not less than 50 kg were selected for the study. All the 
subjects selected are in the age group of 20-40 years and were fasten 
for a minimum of 12 prior to drug formulation administration. The 
protocol approved by the Ethics Committee and subjects provided 
with informed consent. A 300 mg tablet of irbesartan was 
administered orally with 200 mL of water. Blood samples were 
collected at predose and 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 
3.33, 3.67, 4, 4.33, 4.67, 5, 5.5, 6, 8, 10, 12, 16, 24 and 36 h of post 
dose in K2 EDTA vacutainer (5 mL) collection tubes (BD, Franklin, 
NJ, USA). The plasma was collected by centrifugation of blood 
samples at 3200 rpm for 10 min and stored at–70±10 °C till their 
use. Win Nonlin software (Version 5.2) was used to calculate the 
pharmaco kinetic parameters of irbesartan by employing non–
compartmental model were employed for the preset study. 
Mass spectrometry 
Method development starts with the setting of the mass 
spectrometric parameters. A 100 ng/ml solution of irbesartan and 
the IS were injected in to the ESI source of the mass spectrometer 
using infusion pump. Analytes were tuned in positive and negative 
ionization modes, but the highest intense signals and stable 
response was obtained in the positive mode. Data acquisition was 
performed in the multiple reaction monitoring (MRM) modes to 
obtain better selectivity from the endogenous components. The 
source dependent parameters such as curtain gas, collision gas, 
nebulizer gas and auxillary gas were suitably altered to get 
satisfactory and reproducible response. Likewise, compound 
dependent parameters namely collision energy, declustering 
potential and collision cell exit potential were altered to get most 
intense and consistent product ion Q3 MS spectra of analyte and the 
IS. Finally, the most sensitive mass transition was observed from 
m/z 429.5 to 207.0 for irbesartan and from m/z 433.50 to 211.0 for 
the IS. The dwell time for each transition was set at 200 ms.  
Optimization of chromatographic conditions 
Proper selection of mobile phase, flow rate and analytical column 
resulted improved sensitivity and selectivity of an analytical assay. A 
variety of volatile buffers like ammonium acetate and ammonium 
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formate in varying the strengths from 1 mM–20 mM were evaluated 
for their suitability in combination with the organic solvents such as 
methanol and acetonitrile as a isocratic mobile phase. But the results 
obtained were not satisfactory in terms of reproducibility and 
sensitivity. Hence, the acidic buffers namely formic acid and acetic 
acid was tried in combination with methanol and acetonitrile using 
different analytical columns. Finally, an isocratic mobile phase 
composed of 0.2% formic acid and methanol (15:85, v/v) and 
Hypurity advance (50 mm × 4.6 mm, 5 µm) column gave good peak 
shape and response even at lowest concentration level for the 
analyte and the IS. The retention time was obtained for the analyte 
and the IS was 1.3 min with the flow rate of 0.70 mL/min. The total 
chromatographic time was set at 2 min. 
For LC–MS analysis, there must be an appropriate extraction 
technique which can yields maximum recovery with minimal or no 
matrix effect. Hence, SPE was tried with Starata X polymeric sorbent, 
Oasis HLB, Bond Elut Plexa and Orpheus C18 extraction cartridges 
with/without acidic buffer addition to obtain the clean sample and 
to remove the possible interferences. Additionally, SPE provides 
clear extracts than the PP and LLE and the influence on sensitivity is 
significantly less. Of all the above, promising results were obtained 
with Starata X polymeric sorbent cartridge, which can produce a 
clean chromatogram for a blank sample and yields the highest 
recovery for the analyte and the IS from the plasma. Stable labeled 
isotopes as internal standard are helpful in minimizing the matrix 
effect and limit the variable recovery between analyte and the IS. 
Also, these standards will increase the bio analytical assay precision 
and accuracy. Hence, in the present work irbesartan stable labeled 
isotope irbesartan–d4 was employed as an internal standard.  
Chromatography and selectivity 
Method selectivity was assessed by analyzing the 8 extracted blank 
human plasma samples derived from the 8 individual sources. As 
displayed in the fig. 2A, no momentous direct interference in the 
blank plasma traces was observed from endogenous substances in 
drug–free human plasma at the retention time of irbesartan and the 
IS. Moreover, no significant interference was found from the IS to 
the MRM channel of the analyte (fig. 2B). Fig. 2C depicts a 
representative LLOQ sample ion–chromatogram for irbesartan along 
with the IS (50.0 ng/ml). A typical chromatograms resulting from 
the analysis of the subject blank plasma sample and 2 h subject 
plasma sample after the administration of a 300 mg oral single dose 
of irbesartan is shown in the fig. 3. The sample concentration was 
determined to be 3460 ng/ml. 
 
 
Fig. 2: A representative MRM channel chromatograms of irbesartan (left panel) and the IS (right panel) in human blank plasma (A), and 
human plasma spiked with IS (B), a LLOQ sample along with IS 
 
Matrix effect 
Matrix effect experiment was conducted using 8 human plasma lots 
including one hemolytic and lipemic plasma obtained from the 8 
different sources. The average matrix factor valve calculate as the 
response of the post spiked sample/response of neat sample at LQC 
and HQC level was 1.00 and 1.01, which indicated negligible 
suppression or enhancement. 
Sensitivity 
Sensitivity of an analytical method can also be called as the lowest 
limit of reliable quantification (LLOQ) for the analyte. The LLOQ of 
the proposed method was set at 50.0 ng/ml. At this concentration, 
the precision and accuracy results were found to be 3.99% and 
100%, respectively. The signal–to–noise ratio (S/N) at LLOQ level 
was ≥10. 
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Fig. 3: A model MRM channel chromatograms resulting from the analysis of the subject blank plasma sample along with the IS (A) and 2.0 
h subject plasma sample (B), after the administration of a 300 mg oral single dose of irbesartan tablet 
 
Linearity, precision and accuracy  
A total of 5 successful calibration curves were generated during the 
entire course of validation. Linearity of the method was established 
in the concentration range of 10.0–10005 ng/ml. A correlation 
coefficient (r2) of ≥ 0.9936 was obtained for all the runs. Each CC 
was analyzed individually by least square weighted (1/x2
The intra–day precision (%CV) ranged from 0.87 to 4.39% and the 
accuracy was within 103–109%. For inter–day tests, the precision 
(%CV) varied from 4.05 to 7.90% and the accuracy was within 98.1–
104%. The results for intra–day and inter–day precision and 
accuracy results in 6 different quality control levels are summarized 
in table 1. 
) linear 
regression as it produces the best fit for the concentration–detector 
response relationship. The precision and accuracy for calibration 
standards ranged from 96.0% to 106% and 1.35% to 6.31%, 
respectively. 
 
Table 1: Precision and accuracy data for irbesartan 
Quality control Run Concentration found % CV Accuracy (%) 
Intra–day variations (12 replicates at each concentration) 
LLOQ 51.7 ± 2.27 4.39 103 
LQC 150 ± 2.89 1.92 105 
MQC1 1208 ± 12.6 1.04 109 
MQC2 5391 ± 48.2 0.89 107 
HQC 9395 ± 81.8 0.87 105 
Inter–day variations (30 replicates at each concentration) 
LLOQ 49.3 ± 3.89 7.90 98.1 
LQC 142 ± 7.69 5.42 98.8 
MQC1 1153 ± 71.1 6.17 104 
MQC2 5165 ± 209 4.05 103 
HQC 9003 ± 416 4.62 100 
Spiked concentrations of LLOQ, LQC, MQC1, MQC2 and HQC are 50.3, 144, 1105, 5022, and 8968 ng/ml, respectively 
 
Recovery  
The recovery results obtained with the SPE procedure for the 
analyte and the IS was good and reproducible. The mean recovery of 
irbesartan was 84.8±5.55% with the precision (%CV) range of 0.70–
1.43% and the recovery of the IS was 81.4%. 
Dilution integrity 
The real time plasma sample concentrations obtained above the 
upper limit of quantitation (ULOQ) are can be quantified by dilution 
the samples with the blank matrix. The upper concentration limit of 
irbesartan can be extended to 16940 ng/ml by using two–and four–
fold dilution with screened human blank plasma. The precision 
(%CV) for dilution integrity of two–and four–fold dilution was found 
to be 0.87% and 0.95%, whereas the accuracy results were found to 
be 105% and 88.6%, respectively. 
Stability experiments 
Analyte stability in plasma samples under different conditions such 
as bench top stability (12 h), repeated freeze–thaw cycles (4 cycles) 
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and long–term stability at–70 °C for 95 days was evaluated during 
the method validation. Additionally, processed samples stability 
(Reinjection stability 75 h, auto sampler stability 48 h and wet 
extract stability at 2–8 °C 42 h) were also evaluated. The samples 
were considered stable when the mean % nominal values of the 
analyte were found to be within ±15% of the predicted 
concentrations for the analyte at their LQC and HQC levels. The 
results obtained by the various stability tests were summarized in 
the table 2. Therefore, the results were found to be within the 
acceptable limits during the entire validation. 
 
Table 2: Stability data for irbesartan in plasma (n=6) 
Stability test QC (spiked concentration (ng/ml)  Concentration found (ng/ml) %CV Accuracy/Stability (%) 
Bench top 144 a 143± 1.98 1.39 99.5 
 8968 8980 ± 101 1.12 100 
Process 144 b 143 ± 2.94 2.06 99.4 
 8968 8989 ± 116 1.30 100 
Process 144 c 141 ± 2.49 1.76 98.4 
 8968 8968 ± 115 1.28 100 
FT 144 d 142 ± 2.38 1.67 98.9 
 8968 8969 ± 161 1.79 100 
Re–injection 144 e 147 ± 3.51 2.38 103 
 8968 9555 ± 54.0 0.56 107 
Long–term 144 f 140 ± 1.68 1.20 97.2 
 8968 9367± 88.9 0.95 104 
aafter 12 h at room temperature; b after 42 h at 2-8 °C; c after 48 h in auto sampler at 10°C; d after 4 freeze and thaw cycles; e after 75 h of 
Reinjection; f
 
Application of the proposed method 
 at–70 °C for 95 days 
The validated method was then successfully applied to quantify 
irbesartan plasma concentration for a pharma cokinetic study in 
healthy adult male subjects (n=7) under fasting condition. The 
obtained pharma cokinetic results are summarized in the table 3 and 
the mean plasma concentration vs time profile of irbesartan in 
health subjects was shown in the fig. 4. The obtained 
pharmacokinetic results were in close proximity when compared 
with the earlier reports [7]. An incurred sample reanalysis (ISR) 
conducted to authenticate the subject sample concentrations. The 
ISR results obtained were less than 15% difference in 
concentrations (table 4), shows the proposed method is good and 
reproducible.
  
Table 3: Pharmacokinetic parameters of irbesartan after single oral administration of 300 mg tablet to healthy subjects (n=7, mean±SD) 
Parameter Estimated value 
Cmax 3852±492  (ng/ml) 
tmax 2.00±0.47  (h) 
AUC0–t 15605±4319  (ng h/ml) 
AUC0–inf 16281±4214  (ng h/ml) 
t1/2 10.7±4.52  (h) 
 
Table 4: Incurred samples re–analysis data of irbesartan. 
Sample Initial conc. (ng/ml) Re–assay conc. (ng/ml) Differencea (%) 
1 3595 3440 4.42 
2 170 150 12.5 
3 3914 3951 -0.94 
4 157 147 6.76 
5 4219 4279 -1.43 
6 186 165 11.5 
7 3990 3689 7.83 
8 163 154 5.53 
9 3141 3096 1.46 
10 278 269 3.29 
11 3399 3277 3.68 
12 156 159 -1.80 
13 4348 4098 5.91 
14 254 258 -1.67 
a
 
 Expressed as [(initial conc.−re–assay conc.)/average]×100%. 
CONCLUSION 
The LC–MS/MS assay presented in this paper is simple, rapid and 
enough sensitive for the determination of irbesartan in human plasma 
suitable for pharma cokinetic or bioavailability/ bioequivalence 
application in humans. The method was fully validated as per the 
recent US FDA guidelines. Sample extraction with SPE technique with 
direct injection devoid drying and reconstitution steps gave good and 
reproducible recoveries and provides effective sample cleanup. The 
total run time per analysis of each sample is 2.0 min which allows 
analysis of more than 300 samples in a single day. The method showed 
suitability for pharma cokinetic studies in humans. From the results of 
all the validation parameters, we can conclude that the developed 
method can be useful for bioavailability and bioequivalence (BA/BE) 
studies and routine therapeutic drug monitoring with the desired 
precision and accuracy. 
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Fig. 4: Mean plasma concentration–time profile of irbesartan in 
human plasma following oral administration of irbesartan (300 
mg tablet) to healthy volunteers (n=7) 
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